OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO
OBI Pharma is pleased to provide video highlights from the successful company-sponsored symposium that took place at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting in Copenhagen, Denmark, …
To clarify the media report
1. Date of occurrence of the event:2016/09/23 2. Company name: OBI Pharma, Inc. 3. Relationship to the Company (please enter ”head office” or ”affiliatecompany”): N/A 4. Reciprocal shareholding ratios: N/A …
Additional charges on Next Digital Ltd., Hong Kong
1.Parties to the legal matter:OBI Pharma, Inc. 2.Name of the court or disposing agency: (1) Shi Lin District Prosecutors Office (2) Taipei District Court 3.Reference/case numbers of relevant documents:Not available …
The company was invited to participate in 17th Annual Asian Technology Conference organized by Credit Suisse
1.Date of the investor conference:2016/09/08 2.Time of the investor conference: 08:00 3.Location of the investor conference: Grand Hyatt Taipei 4.Brief information disclosed in the investor conference: The company was invited …
Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine
In response to Next Magazine’s continuous and malicious publication of misleading stories against our client, OBI Pharma Inc. (hereinafter referred to as “OBI”), we, Formosan Brothers, Attorneys-at-Law, and EY Taiwan, …
OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting
Experts Examine the Future of Active Immunotherapy in Oncology and the potential role of Adagloxad Simolenin (OBI-822) TAIPEI, TAIWAN, September 6, 2016 – OBI Pharma, Inc., a Taiwan biotech company …
Michael Chang: “the U.S. Department of Justice Had Already Proven My Innocence”
Some media have reported on Dr. Michael Chang, the Chairman of OBI Pharma, Inc. (4174.TWO, hereinafter referred to as OBI) and the former president of the Academia Sinica, Dr. Chi-Huey …
To clarify the media report
1.Date of occurrence of the event:2016/08/31 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliatecompany”): N/A 4.Reciprocal shareholding ratios: N/A 5.Name of mass media: …
Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board
OBI Pharma today announced that Dr. Nathan Chen has resigned his post as Chief Medical Officer for personal reasons, effective from August 10, 2016. Dr. Chen continues to be deeply …
OBI Pharma Inc. announces the change of VP, Chief Medical Officer
1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel(CEO, COO, CMO, CSO, etc.),financial officer, accounting officer, research and development officer, or internal audit officer): VP, Chief Medical Officer …